Morepen Laboratories starts ₹50 cr CDMO supplies in FY27

Update confirms first commercial dispatch

Morepen Laboratories has issued an update on its ₹825 crore Contract Development and Manufacturing Organisation (CDMO) mandate from a leading global pharma major. The company said it has already completed the first commercial dispatch under the program, valued at about ₹50 crore. The dispatch was completed during Q1 FY2026-27 (FY27).

The update is significant because it signals that the contract has moved beyond preparatory work and into actual revenue-generating execution. Morepen said the mandate has successfully transitioned from the validation and qualification stage to the commercial execution stage. This shift typically indicates that product and process requirements have been cleared for commercial supply, subject to ongoing customer schedules and regulatory and commercial conditions.

What the ₹825 crore CDMO mandate covers

The mandate is a multi-year CDMO engagement valued at about ₹825 crore, also reported as USD 91 million. The company has described it as one of the most significant single CDMO mandates in its history. Earlier disclosures stated the supplies were expected to commence within 4 to 5 months, with execution scheduled through Q1 of the following financial year (FY27), subject to customary operational and regulatory processes.

Morepen has also indicated that the contract is expected to serve regulated markets, particularly the US and the EU. While the customer has not been named in the provided information, the company has consistently referred to it as a leading global multinational or global pharma major.

From validation batches to commercial execution

In its Q4 FY26 context, Morepen had said it completed validation batches and aligned initial supply schedules for phased delivery under the CDMO program. The latest update adds that the first commercial dispatch is now complete, which effectively closes the initial ramp-up loop from validation to shipment.

This matters operationally because CDMO contracts often require multiple internal milestones before commercial supplies can begin. Morepen’s statement that it has moved from validation and qualification to commercial execution suggests readiness to supply on a recurring basis, provided delivery schedules and compliance requirements remain aligned.

Near-term supply pipeline: Q1 done, Q2 expected

Morepen expects to scale the program in the coming quarter. It said additional supplies of about ₹225 crore are expected during Q2 FY2026-27. The company has clearly caveated this expectation as being subject to customer schedules and regulatory and commercial requirements.

With the first dispatch of about ₹50 crore already completed in Q1 FY27, the Q2 expectation, if met, would mark a step-up in quarterly supplies under the mandate. However, the company has not provided a month-wise delivery plan or product-level breakdown in the provided text.

Manufacturing capacity build-out: reactors to expand

Alongside the supply update, Morepen said it is strengthening manufacturing infrastructure to support larger CDMO opportunities. The company expects total reactor capacity to reach about 600 KL by the end of Q2. It also outlined a further expansion roadmap toward 800 KL and 1,000 KL in subsequent phases.

The timeline highlights that the near-term milestone is linked to Q2 capacity readiness, while later phases are planned beyond Q2. Morepen did not disclose capex amounts, commissioning dates for the subsequent phases, or the extent to which the additional reactor capacity is tied specifically to the ₹825 crore mandate versus broader CDMO pipeline.

How the announcement fits into FY26 updates

Earlier company communication around Q4 FY26 stated that commercial production commenced under the long-duration manufacturing program. It also said Q4 FY26 marked the commencement of commercial production under the long-duration manufacturing partnership, backed by the multi-year ₹825 crore CDMO mandate received in February 2026.

In a separate FY26-related update, Morepen reported that its Q4 net profit rose 69%. The same update also noted that the board proposed a dividend of 10% to shareholders for FY 2025-26. The provided information does not include the absolute profit figure or the dividend amount per share, and those details are not restated here.

Stock reaction reported around the deal disclosure

Market reaction was visible around the February 2026 disclosure of the CDMO mandate. On February 23, 2026, Morepen Laboratories shares reportedly rose as much as 19% during the day. The stock touched a high of ₹46.90 on the BSE and later settled at ₹45.37, up more than 15%.

While the current update relates to dispatch and execution progress in FY27, the earlier share price move underscores investor sensitivity to CDMO order wins and the visibility they can bring to manufacturing utilisation. The company has not provided a fresh stock move in the latest dispatch update within the supplied text.

Key numbers at a glance

Timeline of disclosed milestones

Market impact and why the execution update matters

The most measurable near-term implication of the update is that the CDMO mandate has moved into commercial dispatches, converting an announced contract into actual supplies. The company’s stated expectation of ~₹225 crore supplies in Q2 FY27, if aligned with customer schedules and regulatory and commercial requirements, points to an intended ramp-up in execution.

The manufacturing infrastructure commentary is also central to the market narrative. Morepen’s reactor capacity targets of ~600 KL by end of Q2, followed by 800 KL and 1,000 KL in later phases, provide an operational lens for how the company is preparing for larger CDMO opportunities. Separately, the contract is expected to serve regulated markets including the US and EU, and Morepen has previously disclosed a fourth consecutive USFDA inspection with zero observations (NIL 483) on April 17, 2026, a data point that supports its positioning for regulated-market manufacturing.

Conclusion

Morepen Laboratories’ latest update confirms that commercial supplies have begun under its ₹825 crore CDMO mandate, with a first dispatch of about ₹50 crore completed in Q1 FY27. The company expects additional supplies of about ₹225 crore in Q2 FY27, subject to customer schedules and regulatory and commercial requirements, and it is working toward expanding reactor capacity to about 600 KL by end of Q2 with further phases planned.